CG Oncology (CGON) Current Assets (2023 - 2026)
CG Oncology's (CGON) quarterly Current Assets came in at $1.1 billion in Q1 2026, up 57.18% YoY from $701.2 million in Q1 2025, and up 45.12% on a QoQ basis from $759.5 million in Q4 2025.
CG Oncology (CGON) Current Assets (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of Current Assets data on file, last reported at $1.1 billion in Q1 2026.
- Quarterly Current Assets rose 57.18% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 57.18% YoY) and the FY2025 annual result came in at $759.5 million, up 0.7% from the prior year.
- Current Assets improved to $1.1 billion in Q1 2026, from $759.5 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $1.1 billion in Q1 2026 to a low of $194.1 million in Q4 2023.
- A 4-year average of $657.5 million and a median of $684.4 million in 2025 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2024 — Current Assets jumped 288.52% — and 2025, when it increased 0.7%.
- Tracing CGON's Current Assets over 4 years: stood at $194.1 million in 2023, then jumped by 288.52% to $754.2 million in 2024, then grew by 0.7% to $759.5 million in 2025, then surged by 45.12% to $1.1 billion in 2026.
- The last three Current Assets figures came in at $1.1 billion (Q1 2026), $759.5 million (Q4 2025), and $695.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn | 1.05 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.05 Bn |
| Mar 31, 2026 | 1.10 Bn |
| Dec 31, 2025 | 759.48 Mn |
| Sep 30, 2025 | 695.79 Mn |
| Jun 30, 2025 | 673.03 Mn |
| Mar 31, 2025 | 701.19 Mn |
| Dec 31, 2024 | 754.21 Mn |
| Sep 30, 2024 | 552.08 Mn |
| Jun 30, 2024 | 563.86 Mn |
| Mar 31, 2024 | 578.61 Mn |
| Dec 31, 2023 | 194.12 Mn |